Prenatal Exposure to Modafinil and the Risk of Major Congenital Anomalies and Other Adverse Neonatal and Pediatric Outcomes
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Melinda Kanoun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unité de Recherche Clinique Necker Cochin, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Modafinil, Prenatal Exposure Delayed Effects, Abnormalities, Drug-Induced, Central Nervous System Stimulants. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To assess the risk of major congenital anomalies (MCAs) and other adverse outcomes following prenatal exposure to modafinil.
Methods
This retrospective cohort study used the French national healthcare database (SNDS) to include singleton children born between January 2009 and September 2024 of women aged 15–55 years. Prenatal exposure to psychostimulants was defined as maternal dispensation during pregnancy. Children prenatally exposed to modafinil were compared with two control groups: children prenatally exposed to methylphenidate and children prenatally unexposed to any psychostimulant matched to the exposed group using propensity‐score matching (PSM). Outcomes included MCAs, neurodevelopmental disorders (NDs), and specialized consultations. Analyses included descriptive statistics, survival analysis, regression models, and dose–response analyses.
Results
Of 10 955 766 included children, 865 were prenatally exposed to modafinil and 950 to methylphenidate. Exposure to modafinil during the first trimester of pregnancy was statistically associated with increased risk of MCA compared to methylphenidate, although the confidence interval was wide and close to the null (aRR = 1.77 [1.01–3.07]). Comparison with PS‐matched unexposed population indicated a possible modest increase in risk, albeit with a wide confidence interval crossing the null (aRR = 1.23 [0.76–1.99]), showing no clear association. Occurrence of NDs (aHR = 0.96 [0.56–1.65]), and specialized consultations (aHR = 1.08 [0.91–1.28]) were similar in the modafinil and PSM unexposed groups but were higher in the methylphenidate group (NDs: aHR = 0.48 [0.29–0.80]; specialized consultations: aHR = 0.71 [0.59–0.85]).
Conclusion
This study shows no increase in neurodevelopmental risk, while a moderate MCA risk cannot be excluded.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unité de Recherche Clinique Necker Cochin, AP-HP, Paris, France.
- Université Paris Cité, Inserm, Pharmacologie et évaluations des thérapeutiques chez l'enfant et la femme enceinte, Paris, France.
- CIC-1419 Inserm, Cochin-Necker, Paris, France.
ORCID-Profile: Mathis Collier
Zitieren
APA
Kanoun, M., Bouazza, N., Treluyer, J. M., & Collier, M. (2026). Prenatal Exposure to Modafinil and the Risk of Major Congenital Anomalies and Other Adverse Neonatal and Pediatric Outcomes. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70448
Vancouver
Kanoun M, Bouazza N, Treluyer JM, Collier M. Prenatal Exposure to Modafinil and the Risk of Major Congenital Anomalies and Other Adverse Neonatal and Pediatric Outcomes. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70448
BibTeX
@article{Kanoun2026,
author = {Kanoun, Melinda and Bouazza, Naïm and Treluyer, Jean-Marc and Collier, Mathis},
title = {Prenatal Exposure to Modafinil and the Risk of Major Congenital Anomalies and Other Adverse Neonatal and Pediatric Outcomes},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70448}
}
EUVIMED